Legend Biotech Corp (NASDAQ:LEGN) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TScan Therapeutics (TCRX – Research ...

After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate ...

In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech (LEGN – Research Report). The ...

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

On Friday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $40.03 which represents a decrease of $-0.92 or -2.25% from the prior close of $40.95. The stock opened at $40.61 and ...

NASDAQ:LEGN opened at $40.03 on Monday. The company has a current ratio of 4.84, a quick ratio of 4.78 and a debt-to-equity ratio of 0.25. Legend Biotech has a 1 year low of $38.60 and a 1 year ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

National Pension Service raised its stake in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 4.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 23,535 shares of the ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Legend Biotech (NASDAQ:LEGN) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.57 and the consensus Revenue Estimate is $146 ...